Concepedia

Janice Darlington

JD

Statistics

Publications

14

Citations

615

H-Index

13

Active since

2009

Affiliations

Amplyx Pharmaceuticals (United States)(Current)

Bridge Pharma (United States)

Cayman Chemical (United States)

Janice Darlington is an author at Amplyx Pharmaceuticals (United States) specializing in pharmacology, molecular pharmacology, and enzyme inhibition.

Publications per year

2009–2017

14

Publications

14

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

J. S. Swaney, Charles W. Chapman, Lucia Correa et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 126 citations

, , +11

Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX

John H. Hutchinson, Martin W. Rowbottom, David Lonergan et al. · ACS Medicinal Chemistry Letters · 2017 · 86 citations · Full text

, , +12

Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)

Martin W. Rowbottom, Gretchen Bain, Imelda Calderon et al. · Journal of Medicinal Chemistry · 2017 · 69 citations · Full text

, , +15

Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding

Adam J. Stein, Gretchen Bain, Pat Prodanovich et al. · Molecular Pharmacology · 2015 · 67 citations

, , +10

Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis

Gretchen Bain, Kristen E. Shannon, Fei Huang et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 56 citations

, , +16

1–5 of 14